These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 7829257)

  • 21. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.
    Tibben JG; Boerman OC; Claessens RA; Corstens FH; van Deuren M; de Mulder PH; van der Meer JW; Keijser KG; Massuger LF
    J Natl Cancer Inst; 1993 Jun; 85(12):1003-4. PubMed ID: 8496973
    [No Abstract]   [Full Text] [Related]  

  • 22. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
    Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
    Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
    Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
    Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
    Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
    Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens.
    Smans KA; Ingvarsson MB; Lindgren P; Canevari S; Walt H; Stigbrand T; Bäckström T; Millán JL
    Int J Cancer; 1999 Oct; 83(2):270-7. PubMed ID: 10471538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
    Buist MR; Kenemans P; van Kamp GJ; Haisma HJ
    Cancer Immunol Immunother; 1995 Jan; 40(1):24-30. PubMed ID: 7828165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.
    Kaneko T; Fusauchi Y; Kakui Y; Masuda M; Akahoshi M; Teramura M; Motoji T; Okumura K; Mizoguchi H; Oshimi K
    Blood; 1993 Mar; 81(5):1333-41. PubMed ID: 8095165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy.
    Ohta S; Tsukamoto H; Watanabe K; Makino K; Kuge S; Hanai N; Habu S; Nishimura T
    Immunol Lett; 1995 Jan; 44(1):35-40. PubMed ID: 7721341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific targeting of in vitro-activated human antitumour effector cells using anti-CD3 x anti-c-erbB-2 bispecific antibody.
    Tsukamoto H; Nakamura Y; Masuko T; Hashimoto Y; Habu S; Nishimura T
    Immunol Cell Biol; 1993 Apr; 71 ( Pt 2)():109-15. PubMed ID: 8098011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
    Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
    Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purification of bispecific F(ab')2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer.
    Warnaar SO; De Paus V; Lardenoije R; Machielse BN; De Graaf J; Bregonje M; Van Haarlem H
    Hybridoma; 1994 Dec; 13(6):519-26. PubMed ID: 7737675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
    Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
    Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
    Thibault C; Nelson H; Chapoval AI
    Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.
    Ruf P; Lindhofer H
    Blood; 2001 Oct; 98(8):2526-34. PubMed ID: 11588051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions.
    Canevari S; Mezzanzanica D; Mazzoni A; Negri DR; Ramakrishna V; Bolhuis RL; Colnaghi MI; Bolis G
    J Hematother; 1995 Oct; 4(5):423-7. PubMed ID: 8581379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
    Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
    Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3.
    van Ravenswaay Claasen HH; van de Griend RJ; Mezzanzanica D; Bolhuis RL; Warnaar SO; Fleuren GJ
    Int J Cancer; 1993 Aug; 55(1):128-36. PubMed ID: 8344744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
    Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
    Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.